RxDoctor Payments Data

Kitty van Meter, NP

Family · Camilla, GANPI 1902005358

Payments from drug & device makers

$729in general payments, 2019–2025

Across 35 payments — averaging $20.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$236
  • Intuitive Surgical$132
  • Novo Nordisk$132
  • AbbVie$68
  • Lilly USA, LLC$63
  • Ultragenyx Pharmaceutical Inc.$31
  • plus $66 from 3 others

What the payments were for

  • Food & beverage$729100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$729 in reported general payments places this provider in the 60th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$27,313
Medicare patients
85
Services billed
624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$37,085
EliquisApixaban47$33,600
MounjaroTirzepatide27$28,282
JardianceEmpagliflozin34$25,266
RybelsusSemaglutide15$18,299
FarxigaDapagliflozin Propanediol17$18,219
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$16,105
JanuviaSitagliptin Phosphate22$12,440
XareltoRivaroxaban17$11,423
TrulicityDulaglutide11$10,576
JanumetSitagliptin Phos/Metformin Hcl14$10,402
MyrbetriqMirabegron15$8,689
AirsupraAlbuterol Sulfate/Budesonide13$6,988
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp12$3,139
Gabapentin142$2,432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$132$55,38446 claims
AstraZenecaFarxiga, Breztri Aerosphere, Airsupra$236$41,31155 claims
Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30$63$40,81052 claims
Boehringer IngelheimJardiance$13$25,26634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,258 family providers in Georgia.

Other family in Camilla

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →